New immune cell therapy takes on tough lymphoma

NCT ID NCT06334991

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 20, 2026 · Updated 10 times

Summary

This early-phase study tests a new treatment called CD19 t-haNK, which uses specially engineered immune cells to target and kill lymphoma cells. It is for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The study will check safety and see if adding the drug rituximab improves results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Albert Cellular Therapy
RECRUITING

Pretoria, Gauteng, 0044, South Africa

Contact Email: •••••@•••••
Dr. Jackie Thomson Inc.
RECRUITING

Johannesburg, Gauteng, 2193, South Africa

Contact Email: •••••@•••••

Contact
FARMOVS
RECRUITING

Bloemfontein, Free State, 9301, South Africa

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED